Home | Contact Us | FAQ | Search & Site Map | Link to Us
Sign In | Join | Other 45 Sites in Network
Home
Discussion Groups
General
GeneralCardiologyVisionDentistryPharmacyLaboratoryNutritionAlternative
Diseases and Disorders
AIDSAlzheimer'sArthritisAsthmaCancerBreast CancerDiabetesEpilepsyGlaucomaHepatitisHerpesLupusProstate BPHProstate CancerProstatitisSinusitisTinnitus

Medical Forum / General / Vision / November 2006

Tip: Looking for answers? Try searching our database.

SLT Becomes First-Line Treatment for Glaucoma

Thread view: 
Enable EMail Alerts  Start New Thread
Thread rating: 
Irv Arons - 23 Nov 2006 19:10 GMT
In addition to the information about Avastin/Lucentis, I have also
posted information about the use of the Selecta laser to treat glaucoma
using "Selective Laser Trabuculoplasty" or SLT. It appears that the use
of SLT is becoming a first-line treatment for glaucoma, in place of
drug therapy.

The article is entitled: An Update on the Use of SLT for Treating
Glaucoma

and the web reference is:
http://irvaronsjournal.blogspot.com/2006/11/update-on-use-of-slt-for-treating.html

This update is also from Michael Lachman's EyeQ Report No. 9, from the
recent AAO meeting held in Las Vegas. There is a link to this report in
my web posting.

Irv Arons
Dr. Leukoma - 24 Nov 2006 00:44 GMT
> In addition to the information about Avastin/Lucentis, I have also
> posted information about the use of the Selecta laser to treat glaucoma
> using "Selective Laser Trabuculoplasty" or SLT. It appears that the use
> of SLT is becoming a first-line treatment for glaucoma, in place of
> drug therapy.

Of course it is, Irv, because optometry is now using topical meds to
treat glaucoma.  We also know that SLT needs to be repeated.  But, is
it repeatable forever, or just until filtering surgery is required?
Aren't you the same person who promotes refractive surgery?

DrG
Irv Arons - 24 Nov 2006 01:40 GMT
> > In addition to the information about Avastin/Lucentis, I have also
> > posted information about the use of the Selecta laser to treat glaucoma
[quoted text clipped - 8 lines]
>
> DrG

DrG,

I don't promote anything -- am/was an ophthalmic journalist for over 20
years and just report on what I learn.

In my original article on SLT (published in Ocular Surgery News in
2001), I interviewed the inventor of the laser procedure and based on
what I learned from him, thought that SLT would eventually become a
first-line treatment, which now appears to be the case.

I also have written extensively on new developments in refractive
surgery, again based on what I learned from attending both ASCRS and
AAO meetings and writing the Technology Update column for Ocular
Surgery News for about 10 years.

Regards,

Irv Arons
p.clarkii@gmail.com - 24 Nov 2006 02:54 GMT
actually laser treatment already IS pretty much the first line
treatment in europe (ALT).  in the US we seem to prefer using medical
therapy first.  when they work, laser treatments have advantages over
medical treatment-- better patient compliance, reduced cost (over the
long haul), etc.

i think it might be overly cynical to suggest that SLT might become
first line as a way to shut optometry out of treating glaucoma.
controlled studies will define the treatment of choice
===========

> > > In addition to the information about Avastin/Lucentis, I have also
> > > posted information about the use of the Selecta laser to treat glaucoma
[quoted text clipped - 27 lines]
>
> Irv Arons
Dr. Leukoma - 24 Nov 2006 03:39 GMT
> actually laser treatment already IS pretty much the first line
> treatment in europe (ALT).  in the US we seem to prefer using medical
[quoted text clipped - 6 lines]
> controlled studies will define the treatment of choice
> ===========

Am I being overly cynical?  I don't think so.  I'm merely calling into
question the long term efficacy of this as a first line defense.  It
has nothing to do with shutting optometry out of treating glaucoma,
which is an absurd suggestion.  Can you tell us this, Irv?

By the way, do you treat glaucoma?

DrG
LarryDoc - 24 Nov 2006 06:54 GMT
> actually laser treatment already IS pretty much the first line
> treatment in europe (ALT).  in the US we seem to prefer using medical
> therapy first.  when they work, laser treatments have advantages over
> medical treatment-- better patient compliance, reduced cost (over the
> long haul), etc.

And this, I think, is an issue that warrants further discussion.  In
many parts of the civilized world ALT is indeed the first line treatment
while here in the good 'ole USA, it's try one med, then another, then
perhaps add a second med, then another and then when that doesn't work
(because drug therapy simply fails or the patient can not or will not be
complaint) only then do we go for the laser.

One would think that a larger patient base undergoing laser surgery and
filtering surgeries for glaucoma would ultimately yield better
techniques, not to mention a good statistical analysis of the efficacy
of doing so.  

Considering that we went for what----20-30 years with no real change in
pharmaceutical therapy before the "new wave" of meds hit the market,
while on the other side of the pond ALT became the standard of care, it
looks to me that if we want to look at conspiracy theory, that's a good
place to start.

LB, O.D.
Dr. Leukoma - 24 Nov 2006 13:01 GMT
I treat glaucoma in my practice, and I understand first-hand the
problem with medical compliance.  In fact, I am about to refer an
elderly patient for SLT.

If you want to know what the stink is about, here is one glaucoma
specialist's opinion from the glaucoma newsgroup:

http://makeashorterlink.com/?I1223514E

Also, the first abstract I came across when doing a Medline search is a
recent study from the Journal of Glaucoma:
________________________________________________________________
High failure rate associated with 180 degrees selective laser
trabeculoplasty.

J Glaucoma.  2005; 14(5):400-8 (ISSN: 1057-0829)
Song J; Lee PP; Epstein DL; Stinnett SS; Herndon LW; Asrani SG;
Allingham RR; Challa P
Department of Ophthalmology, Duke University Medical Center, Durham,
North Carolina NC 27710, USA.

PURPOSE: To determine the efficacy of selective laser trabeculoplasty
(SLT) in a tertiary care referral center. (SNIP)

By survival/life-table analysis, mean time to failure was 6 months and
5.5 months, by definitions one and two, respectively. By the end of the
study (14.5 months), the failure rates were 86% and 92% by definitions
one and two, respectively. By each definition, in both univariable and
multivariable analysis, only lower baseline IOP was a significant
predictor of failure.

CONCLUSIONS: Selective laser trabeculoplasty had an overall low success
rate in our tertiary clinic population, with overall failure rates of
68% to 74% in those who underwent 180 degrees selective laser
trabeculoplasty
_____________________________________________________________

DrG

> > actually laser treatment already IS pretty much the first line
> > treatment in europe (ALT).  in the US we seem to prefer using medical
[quoted text clipped - 21 lines]
>
> LB, O.D.
Dr. Leukoma - 24 Nov 2006 03:41 GMT
> I also have written extensively on new developments in refractive
> surgery, again based on what I learned from attending both ASCRS and
> AAO meetings and writing the Technology Update column for Ocular
> Surgery News for about 10 years.

>From the AAO and ASCRS to your pen.  These are the same folks that made
the ridiculous assertion that LASIK is safer than contact lenses?

DrG
serebel - 24 Nov 2006 03:53 GMT
> > I also have written extensively on new developments in refractive
> > surgery, again based on what I learned from attending both ASCRS and
[quoted text clipped - 5 lines]
>
> DrG

Leukoma's jealousy rides on. You read Irv's post stating he's a
JOURNALIST. Why would you ask if he treats eyes?
Dr. Leukoma - 24 Nov 2006 03:55 GMT
> > > I also have written extensively on new developments in refractive
> > > surgery, again based on what I learned from attending both ASCRS and
[quoted text clipped - 8 lines]
> Leukoma's jealousy rides on. You read Irv's post stating he's a
> JOURNALIST. Why would you ask if he treats eyes?

I'm not directing my question at Irv.  I directed it at the other
person who posted.

Do you have something useful to add to this discussion?  If so, I would
like to see it.

DrG
serebel - 24 Nov 2006 04:55 GMT
> Do you have something useful to add to this discussion?  If so, I would
> like to see it.
>
> DrG

I'll add as I see fit, I don't see a hall monitor's badge on you.
Irv Arons - 24 Nov 2006 05:25 GMT
> > Do you have something useful to add to this discussion?  If so, I would
> > like to see it.
> >
> > DrG
>
> I'll add as I see fit, I don't see a hall monitor's badge on you.

Hey guys, cool the rhetoric. I didn't mean to start a street fight,
just wanted to pass along what I thought was some useful information
for those seeking treatment for glaucoma.

Irv Arons
Dr. Leukoma - 24 Nov 2006 13:16 GMT
> Hey guys, cool the rhetoric. I didn't mean to start a street fight,
> just wanted to pass along what I thought was some useful information
> for those seeking treatment for glaucoma.

Are patients really in a position to properly evaluate the various
treatment options for glaucoma?  With regard to SLT, when I see my
local glaucoma specialists using it as a first line treatment, and then
if I see that medical therapy is still effective once SLT has
permanently lost its effect, then I'll jump on that bandwagon.  If SLT
loses its effectiveness and has destroyed the trabecular meshwork to
the point where medical therapy is no longer effective, then the only
remaining option is filtering surgery, which is not a walk in the park
for the patient.

DrG
Dr. Leukoma - 24 Nov 2006 14:12 GMT
Stopping Glaucoma with a Stick in the Eye

Incubator spin-off Transcend Medical wants to change the way glaucoma
is treated.
November 10, 2006

On Friday, ophthalmic incubator ForSight Labs hatched its first
company. Meet Transcend Medical, a company focused on stopping glaucoma
before it can seriously impair sight.

The Menlo Park, California-based company is out to replace current
surgical approaches for treating glaucoma with a less invasive
procedure. "And what's unique is that it can be performed right
there in the (doctor's) office," said Transcend's CEO Mitchell
Campbell, as opposed to a surgical setting.

Transcend has developed a synthetic tube that is implanted to help
ensure the eye's fluid flow to maintain a healthy level of pressure
within the eye.

When fluid, called aqueous fluid, becomes blocked, pressure builds
within the eye causing damage to the optic nerve, which can eventually
lead to blindness.

But the potential breakthrough that Transcend offers is the ability to
place the device with a needle stick delivery, rather than having to
make an incision.

> In addition to the information about Avastin/Lucentis, I have also
> posted information about the use of the Selecta laser to treat glaucoma
[quoted text clipped - 13 lines]
>
> Irv Arons
Anon E. Muss - 24 Nov 2006 19:01 GMT
>In addition to the information about Avastin/Lucentis, I have also
>posted information about the use of the Selecta laser to treat glaucoma
>using "Selective Laser Trabuculoplasty" or SLT. It appears that the use
>of SLT is becoming a first-line treatment for glaucoma, in place of
>drug therapy.

If I had a choice between lifelong topical medicationS vs SLT (if it
would give me a reasonable chance of having to forego or not use
topical medications for at least a few years) for the treatment of my
POAG (or pigmentary glaucoma), I would *probably* choose SLT.  If I
get could get by with a topical prostaglandin analog (1 gtt qHS)
alone, it would be a harder decision.  If it would give me a good
chance at say going from a topical beta-blocker AND a prostanglandin
analog to just the latter, I would *probably* choose SLT.

I am not alone.

I have no published reference for what follows, only what was told to
me by a local fellowship-trained glaucoma OMD:

A group of glaucoma specialists were interviewed and asked what their
first choice of treatment for their POAG patients was ALT/SLT or
topical medications.  The vast majority of them said topical
medications.  When the question was changed to be what would YOU
choose as a first-line treatment for YOUSELF if you had POAG, the
answer was ALT/SLT.

Laser surgery is surgery, but the incidence of side effects is low
with SLT and I certainly understand the power and benefits of doing a
simple outpatient procedure if it would give me a great shot at
eliminating, delaying or reducing the amount of topical medications I
was using to treat my POAG.

FWIW, in Europe, filtering surgery is many times the first-line choice
for glaucoma treatment, although I would certainly not choose this for
glaucoma that could be controlled with a 2-3 topical medications +/-
ALT/SLT.
Dr. Leukoma - 24 Nov 2006 19:15 GMT
Glaucoma is a lifetime disease, therefore you are buying time with the
treatment.

Electing ALT as the first line treatment will leave you with no other
option but filtration surgery when ALT fails, and it will fail.  It
simply destroys the trabecular meshwork.

Certainly SLT causes less destruction because the laser produces less
energy, and so the end game is prolonged over ALT.

When medical management fails, you've got two more options: SLT and
filtration surgery.

Should ALT be the first line treatment when medical management is
available?  Probably not.  With SLT, the answer is not as clear at
least in some cases.

DrG

> >In addition to the information about Avastin/Lucentis, I have also
> >posted information about the use of the Selecta laser to treat glaucoma
[quoted text clipped - 33 lines]
> glaucoma that could be controlled with a 2-3 topical medications +/-
> ALT/SLT.
Anon E. Muss - 24 Nov 2006 21:35 GMT
>Glaucoma is a lifetime disease, therefore you are buying time with the
>treatment.

And what is the goal of current glaucoma therapy?

To reduce *if necessary* the intraocular pressure to the point that
you buy a patient enough time to maintain good quality of life by the
time the patient expires.

>Electing ALT as the first line treatment will leave you with no other
>option but filtration surgery when ALT fails

Not true.  In most patients, many topical antiglaucoma medications
still have efficacy after SLT.

>and it will fail.

It's all about risk assessment.  That SLT fails eventually may be
unimportant if the SLTs buys the patient "enough time."

"Enough time" is crucial.  It's why many of us choose not to treat at
all some of our patients will definite and clear-cut glaucoma.

>When medical management fails, you've got two more options: SLT and
>filtration surgery.

You've got other options.  Endoscopic cyclodestructive procedures are
showing great promise also.  And I expect years down the road we will
have superior glaucoma surgery options that what is available today.

>Should ALT be the first line treatment when medical management is
>available?  Probably not.  With SLT, the answer is not as clear at
>least in some cases.

The real answer is "It Depends".

See you in Denver in a couple weeks?
Dr. Leukoma - 25 Nov 2006 03:09 GMT
ALT loses effectiveness, and after about two treatments the patient is
left with a trabecular meshwork that is refractory to medical therapy.
Maybe this won't happen with SLT, but maybe it's just a bit premature
to be touting it as a first-line treatment in patients who are
compliant and can tolerate prostaglandin analogues.  It does alter the
meshwork, it just doesn't fry it like the ALT.

Everyone's entitled to their opinion, and it appears that Irv got his
money's worth out of his news release.

DrG

> >Glaucoma is a lifetime disease, therefore you are buying time with the
> >treatment.
[quoted text clipped - 33 lines]
>
> See you in Denver in a couple weeks?
Irv Arons - 25 Nov 2006 04:18 GMT
> ALT loses effectiveness, and after about two treatments the patient is
> left with a trabecular meshwork that is refractory to medical therapy.
[quoted text clipped - 45 lines]
> >
> > See you in Denver in a couple weeks?

Dr. G,

My post was not based on a news release, but rather the reporting of
Michael Lachman, an industry consultant, based on his interviews of
glaucoma specialists and a scientific poster presented at the AAO
meeting. For all the details please take a look at his EyeQ Report No.
9, which is linked in my web site.

Regards,

Irv Arons
serebel - 26 Nov 2006 01:06 GMT
> My post was not based on a news release, but rather the reporting of
> Michael Lachman, an industry consultant, based on his interviews of
[quoted text clipped - 5 lines]
>
> Irv Arons

  Doesn't matter how or what you post, leukoma will spin it anyway.

Rate this thread:






 
Sign In
Join
My Latest Posts
My Monitored Threads
My Blog
My Photo Gallery
My Profile
My Homepage

Start New Thread
Enable EMail Alerts
Rate this Thread



©2008 Advenet LLC   Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.